Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MASL in Oral Squamous Cell Carcinoma and Precancerous Lesions
NCT04188665Phase 1Completed
- Sponsor
- Rowan University
- Start
- Jan 2021
- Primary completion
- Dec 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised trial of maackia amurensis seed lectin in oral squamous cell carcinoma (OSCC) and oral leukoplakia (2 arms), sponsored by Rowan University. Primary endpoint: Pre-treatment OSCC Morphology and PDPN Expression at 1 day. Started Jan 2021; status: completed.
02
Drugs
maackia amurensis seed lectin
03
Conditions
oral squamous cell carcinoma (OSCC)oral leukoplakia
Beyond the preview
Go deeper on NCT04188665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04188665.